Beliefs about COVID-19 testing and treatment: A national survey of Black and White adults
Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatien...
Saved in:
| Published in | Public health in practice (Oxford, England) Vol. 8; p. 100519 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.12.2024
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2666-5352 2666-5352 |
| DOI | 10.1016/j.puhip.2024.100519 |
Cover
| Abstract | Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease.
Cross-sectional structured survey.
Respondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access.
Overall, awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31–2.33]) as were higher income respondents (1.13, 95 % CI [1.08–1.17]) and self-identified Liberals (1.79, 95 % CI [1.29–2.49]).
Clinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs.
[Display omitted] |
|---|---|
| AbstractList | AbstractObjectivesKnowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease. Study designCross-sectional structured survey. MethodsRespondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access. ResultsOverall , awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31–2.33]) as were higher income respondents (1.13, 95 % CI [1.08–1.17]) and self-identified Liberals (1.79, 95 % CI [1.29–2.49]). ConclusionsClinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs. Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease. Cross-sectional structured survey. Respondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access. Overall, awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31–2.33]) as were higher income respondents (1.13, 95 % CI [1.08–1.17]) and self-identified Liberals (1.79, 95 % CI [1.29–2.49]). Clinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs. [Display omitted] Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease. Cross-sectional structured survey. Respondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access. Overall awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31-2.33]) as were higher income respondents (1.13, 95 % CI [1.08-1.17]) and self-identified Liberals (1.79, 95 % CI [1.29-2.49]). Clinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs. Objectives: Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease. Study design: Cross-sectional structured survey. Methods: Respondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access. Results: Overall, awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31–2.33]) as were higher income respondents (1.13, 95 % CI [1.08–1.17]) and self-identified Liberals (1.79, 95 % CI [1.29–2.49]). Conclusions: Clinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs. Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease.ObjectivesKnowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus (COVID-19) in the United States. This study measured knowledge, attitude, behaviors, and self-reported barriers towards COVID-19 testing and outpatient anti-viral medications (OPA) treatments among Black and older individuals who face greater hospitalization and mortality from the disease.Cross-sectional structured survey.Study designCross-sectional structured survey.Respondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access.MethodsRespondents were randomly selected from an opt-in national panel in December 2022. Equal numbers of Black and White US adults over the age of 40 (n = 1037) completed the 42 item online survey. The main measures were key sociodemographic variables of respondents, race, age, political affiliation and COVID-19 attitudes, beliefs, testing behaviors, and knowledge and barriers to OPA access.Overall, awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31-2.33]) as were higher income respondents (1.13, 95 % CI [1.08-1.17]) and self-identified Liberals (1.79, 95 % CI [1.29-2.49]).ResultsOverall, awareness and knowledge of COVID-19 outpatient treatments was low. Black respondents were more likely to test for COVID-19 than White respondents but less likely to know about OPA treatments. Insurance coverage was a significant factor in use of home tests. Knowledge of OPA treatments was low across groups. White respondents were more likely than Black respondents to be aware of OPA treatments (1.75, 95 % CI [1.31-2.33]) as were higher income respondents (1.13, 95 % CI [1.08-1.17]) and self-identified Liberals (1.79, 95 % CI [1.29-2.49]).Clinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs.ConclusionsClinicians should know large numbers of patients may not be testing for COVID-19, nor are they aware of outpatient treatment options and may hold inaccurate beliefs about them. Developing culturally specific patient education materials are warranted to increase testing, utilization of vaccinations and OPAs. Image 1 |
| ArticleNumber | 100519 |
| Author | Blunt, Ryan Barker, K. Laura Alolod, Gerard P. Patel, Jay S. Siminoff, Laura A. Litsas, Diana |
| Author_xml | – sequence: 1 givenname: Laura A. orcidid: 0000-0002-6775-665X surname: Siminoff fullname: Siminoff, Laura A. email: lasiminoff@temple.edu organization: Department of Social and Behavioral Sciences, College of Public Health, Temple University, USA – sequence: 2 givenname: K. Laura surname: Barker fullname: Barker, K. Laura organization: Department of Social and Behavioral Sciences, College of Public Health, Temple University, USA – sequence: 3 givenname: Ryan orcidid: 0000-0002-2169-7797 surname: Blunt fullname: Blunt, Ryan organization: Department of Social and Behavioral Sciences, College of Public Health, Temple University, USA – sequence: 4 givenname: Diana orcidid: 0000-0003-2018-4962 surname: Litsas fullname: Litsas, Diana organization: Department of Social and Behavioral Sciences, College of Public Health, Temple University, USA – sequence: 5 givenname: Gerard P. orcidid: 0000-0001-7137-5967 surname: Alolod fullname: Alolod, Gerard P. organization: Department of Social and Behavioral Sciences, College of Public Health, Temple University, USA – sequence: 6 givenname: Jay S. surname: Patel fullname: Patel, Jay S. organization: Health Services Administration and Policy, College of Public Health, Temple University, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39027346$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkttuEzEQhleoiJbSJ0BCvuQmwYe1dw0C1IZTpEq94CSuLMeeTZ1u7GB7I-Xt8TalapFQr2yP__lGM_M_rQ588FBVzwmeEkzEq9V0M1y6zZRiWpcI5kQ-qo6oEGLCGacHd-6H1UlKK4wx5YQ0bf2kOmQS04bV4qj6dQa9gy4hvQhDRrOLH_MPEyJRhpSdXyLtLcoRdF6Dz6_RKfI6u-B1j9IQt7BDoUNnvTZX18qfly4D0nboc3pWPe50n-Dk5jyuvn_6-G32ZXJ-8Xk-Oz2fGN6yPKlNwwCotLyWXVfzBlppG2sFFQ1eYMlbKTrGoSV1Z4gEucDQ6haDbUEzumDH1XzPtUGv1Ca6tY47FbRT14EQl0rH7EwPijcUpDWGYNvWmnItG-iM7oRoykPwwnq_Z22GxRqsKT1H3d-D3v_x7lItw1YRQjnHUhbCyxtCDL-HMkS1dslA32sPYUiK4ZYKhplgRfribrHbKn-XUwRsLzAxpBShu5UQrEYXqNLv6AI1ukDtXVCy3u6zoAx96yCqZBx4A9ZFMLlMxT2Q_-6ffNM774zur2AHaRWGWNafFFGJKqy-jj4bbUbrYjEuRsCb_wMeLP8HrELi8A |
| Cites_doi | 10.3201/eid2808.212200 10.2105/AJPH.2021.306244 10.1007/s11606-023-08106-6 10.1001/jamanetworkopen.2023.28928 10.1016/S2589-7500(20)30318-6 10.1371/journal.pone.0252658 10.1021/acsnano.1c02981 10.1016/j.amepre.2020.05.001 10.31219/osf.io/w3qpb 10.1016/j.ahr.2022.100066 10.1016/j.vaccine.2021.01.010 10.1186/s12889-021-12432-x 10.1001/jamanetworkopen.2021.17074 10.1016/j.puhe.2022.08.003 10.1080/21565503.2017.1419433 10.3389/fpsyg.2022.926664 10.2105/AJPH.2021.306558 10.1080/13548506.2021.1969026 10.3390/ijerph18052278 10.7326/M22-2141 10.7326/M20-3936 10.3390/ijerph18094848 10.1056/NEJMp1700736 10.1016/j.sapharm.2020.04.032 10.1038/s41562-021-01056-1 10.1016/j.annepidem.2021.03.001 10.1001/jamanetworkopen.2022.35837 10.3390/vaccines10030476 10.1001/jama.2023.16666 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors The Authors 2024 The Authors. 2024 The Authors 2024 |
| Copyright_xml | – notice: 2024 The Authors – notice: The Authors – notice: 2024 The Authors. – notice: 2024 The Authors 2024 |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1016/j.puhip.2024.100519 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Public Health |
| EISSN | 2666-5352 |
| EndPage | 100519 |
| ExternalDocumentID | oai_doaj_org_article_572e9dcc10d84a25a97efcaf66725a65 PMC11255099 39027346 10_1016_j_puhip_2024_100519 S2666535224000569 1_s2_0_S2666535224000569 |
| Genre | Journal Article |
| GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AALRI AAXUO AAYWO ACLIJ ACVFH ADCNI ADVLN AEUPX AFJKZ AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM Z5R AFCTW 6I. AAFTH AAYXX CITATION AAHOK NCXOZ NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c583t-4c73ee29d549ff457e89d7dd62670b095896f35e814fc19e9b0e8a80ed8ea32b3 |
| IEDL.DBID | DOA |
| ISSN | 2666-5352 |
| IngestDate | Wed Aug 27 01:15:08 EDT 2025 Thu Aug 21 18:32:57 EDT 2025 Fri Sep 05 12:55:07 EDT 2025 Wed Feb 19 02:04:15 EST 2025 Thu Aug 07 07:21:23 EDT 2025 Sat Sep 06 17:18:25 EDT 2025 Fri Aug 08 06:00:32 EDT 2025 Tue Aug 26 16:33:59 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | COVID-19 attitudes and knowledge Infectious disease prevention Antiviral treatment Health communication Health disparities |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. 2024 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c583t-4c73ee29d549ff457e89d7dd62670b095896f35e814fc19e9b0e8a80ed8ea32b3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-6775-665X 0000-0001-7137-5967 0000-0002-2169-7797 0000-0003-2018-4962 |
| OpenAccessLink | https://doaj.org/article/572e9dcc10d84a25a97efcaf66725a65 |
| PMID | 39027346 |
| PQID | 3082630363 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_572e9dcc10d84a25a97efcaf66725a65 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11255099 proquest_miscellaneous_3082630363 pubmed_primary_39027346 crossref_primary_10_1016_j_puhip_2024_100519 elsevier_sciencedirect_doi_10_1016_j_puhip_2024_100519 elsevier_clinicalkeyesjournals_1_s2_0_S2666535224000569 elsevier_clinicalkey_doi_10_1016_j_puhip_2024_100519 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-12-01 |
| PublicationDateYYYYMMDD | 2024-12-01 |
| PublicationDate_xml | – month: 12 year: 2024 text: 2024-12-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Public health in practice (Oxford, England) |
| PublicationTitleAlternate | Public Health Pract (Oxf) |
| PublicationYear | 2024 |
| Publisher | Elsevier Ltd Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier |
| References | House (bib15) Published October 7, 2022. Accessed November 8, 2022. Sule, DaCosta, DeCou, Gilson, Wallace, Goff (bib42) 2023; 6 Administration for Strategic Preparedness & Response. Test to Treat | HHS/ASPR. Accessed October 21, 2022. Sun, Hua, Qiu, Brown (bib49) 2022; 2 Valera, Jankelow, Lim (bib35) 2021; 15 Dryden-Peterson, Kim, Kim (bib21) 2023; 176 Barreto, Frasure-Yokley, Vargas, Wong (bib47) 2018; 6 Milligan, Hoyt, Gold, Hiserodt, Otto (bib13) 2022; 27 NIH launches Home Test to Treat, a pilot COVID-19 telehealth program. National Institute of Biomedical Imaging and Bioengineering. Accessed September 14, 2023. Recht (bib26) April 15, 2022 Zarębska-Michaluk, Rzymski, Moniuszko-Malinowska (bib14) 2022; 10 Menikoff, Kaneshiro, Pritchard (bib46) 2017; 376 Hill, Artiga (bib6) August 22, 2022 McElfish, Purvis, James, Willis, Andersen (bib50) 2021; 18 Facente, De Zuzuarregui, Frank (bib37) 2022; 13 Katella (bib20) January 5, 2024 Asabor, Warren, Cohen (bib28) 2022; 112 Perry (bib30) 2021; 111 Dayton, Song, Kaloustian, Eschliman, Strickland, Latkin (bib52) 2022; 212 bib45 (bib3) January 11, 2023 . Mackey, Purushothaman, Haupt, Nali, Li (bib40) 2021; 3 Adepoju, Ojinnaka (bib31) 2021; 24 Billock, Steege, Miniño (bib4) 2020 bib1 Levy, Thorpe, Scherer (bib34) 2022; 5 bib51 (bib2) January 18, 2023 (bib22) 2023 Sharmin R, Rayna SE, Khalequzzaman M, Rahman KMT, Islam SS. COVID-19 Testing: Perceived Barriers Among the Urban Slum Dwellers of Dhaka, Bangladesh. doi:10.31219/OSF.IO/W3QPB. Wong, Haderlein, Yuan, Moy, Jones, Washington (bib7) 2021; 18 Albrecht (bib11) 2022; 22 Ali, Tozan, Jones, Foreman, Capasso, DiClemente (bib32) 2021; 58 Leonhardt D. The Power of Paxlovid. The New York Times. (bib8) 2022 Bilal, Tabb, Barber, Diez Roux (bib29) 2021; 174 Erku, Belachew, Abrha (bib41) 2021; 17 Bruine de Bruin, Bennett (bib36) 2020; 59 Oakley ERS and EM. Geospatial Disparities in Federal COVID-19 Test-to-Treat Program | EndNote Click. Accessed May 20, 2023. Loomba, de Figueiredo, Piatek, de Graaf, Larson (bib39) 2021; 5 Benchimol-Elkaim, Dryden-Peterson, Miller, Koh, Geller (bib16) 2023 Jimenez, Rivera-Núñez, Crabtree (bib38) 2021; 4 Perry, Aronson, Railey, Ludema (bib33) 2021; 16 bib25 Lin, Deng, Ryan (bib5) 2022; 28 Verderosa MAB and AD. Use of Antiviral Agents and other Therapies for COVID-19 | EndNote Click. Accessed May 20, 2023. (bib9) 2023 Raglow Z, Malani PN, Petty LA. Outpatient treatment for COVID-19. JAMA. Published online August 16, 2023. doi:10.1001/jama.2023.16666. Parums (bib44) 2022; 28 Katella (bib19) March 25, 2024 Kates, Tolbert, Rouw (bib10) 2022 Ruiz, Bell (bib12) 2021; 39 Perry (10.1016/j.puhip.2024.100519_bib30) 2021; 111 Ali (10.1016/j.puhip.2024.100519_bib32) 2021; 58 Recht (10.1016/j.puhip.2024.100519_bib26) 2022 Bruine de Bruin (10.1016/j.puhip.2024.100519_bib36) 2020; 59 Dryden-Peterson (10.1016/j.puhip.2024.100519_bib21) 2023; 176 Lin (10.1016/j.puhip.2024.100519_bib5) 2022; 28 Bilal (10.1016/j.puhip.2024.100519_bib29) 2021; 174 (10.1016/j.puhip.2024.100519_bib2) 2023 (10.1016/j.puhip.2024.100519_bib8) 2022 Perry (10.1016/j.puhip.2024.100519_bib33) 2021; 16 Katella (10.1016/j.puhip.2024.100519_bib20) 2024 Valera (10.1016/j.puhip.2024.100519_bib35) 2021; 15 10.1016/j.puhip.2024.100519_bib18 10.1016/j.puhip.2024.100519_bib17 Jimenez (10.1016/j.puhip.2024.100519_bib38) 2021; 4 Mackey (10.1016/j.puhip.2024.100519_bib40) 2021; 3 Barreto (10.1016/j.puhip.2024.100519_bib47) 2018; 6 Asabor (10.1016/j.puhip.2024.100519_bib28) 2022; 112 Sun (10.1016/j.puhip.2024.100519_bib49) 2022; 2 Hill (10.1016/j.puhip.2024.100519_bib6) 2022 Erku (10.1016/j.puhip.2024.100519_bib41) 2021; 17 Menikoff (10.1016/j.puhip.2024.100519_bib46) 2017; 376 Katella (10.1016/j.puhip.2024.100519_bib19) 2024 McElfish (10.1016/j.puhip.2024.100519_bib50) 2021; 18 Dayton (10.1016/j.puhip.2024.100519_bib52) 2022; 212 Ruiz (10.1016/j.puhip.2024.100519_bib12) 2021; 39 Loomba (10.1016/j.puhip.2024.100519_bib39) 2021; 5 Milligan (10.1016/j.puhip.2024.100519_bib13) 2022; 27 (10.1016/j.puhip.2024.100519_bib22) 2023 Billock (10.1016/j.puhip.2024.100519_bib4) 2020 Wong (10.1016/j.puhip.2024.100519_bib7) 2021; 18 Adepoju (10.1016/j.puhip.2024.100519_bib31) 2021; 24 Albrecht (10.1016/j.puhip.2024.100519_bib11) 2022; 22 Parums (10.1016/j.puhip.2024.100519_bib44) 2022; 28 Zarębska-Michaluk (10.1016/j.puhip.2024.100519_bib14) 2022; 10 House (10.1016/j.puhip.2024.100519_bib15) 10.1016/j.puhip.2024.100519_bib27 Facente (10.1016/j.puhip.2024.100519_bib37) 2022; 13 Sule (10.1016/j.puhip.2024.100519_bib42) 2023; 6 10.1016/j.puhip.2024.100519_bib48 10.1016/j.puhip.2024.100519_bib24 10.1016/j.puhip.2024.100519_bib23 Kates (10.1016/j.puhip.2024.100519_bib10) 10.1016/j.puhip.2024.100519_bib43 Benchimol-Elkaim (10.1016/j.puhip.2024.100519_bib16) 2023 Levy (10.1016/j.puhip.2024.100519_bib34) 2022; 5 |
| References_xml | – volume: 15 start-page: 7899 year: 2021 end-page: 7906 ident: bib35 article-title: COVID-19 point-of-care diagnostics: present and future publication-title: ACS Nano – year: August 22, 2022 ident: bib6 article-title: COVID-19 Cases and Deaths by Race/Ethnicity: Current Data and Changes over Time – year: 2023 ident: bib9 article-title: COVID-19 provisional counts - health disparities – year: April 15, 2022 ident: bib26 article-title: How the Test-To-Treat Pillar of the US Covid Strategy Is Failing Patients – volume: 112 start-page: 518 year: 2022 end-page: 526 ident: bib28 article-title: Racial/ethnic segregation and access to COVID-19 testing: spatial distribution of COVID-19 testing sites in the four largest highly segregated cities in the United States publication-title: Am. J. Publ. Health – year: January 18, 2023 ident: bib2 article-title: Leading Causes of Death – volume: 6 year: 2023 ident: bib42 article-title: Communication of COVID-19 misinformation on social media by physicians in the US publication-title: JAMA Netw. Open – reference: Administration for Strategic Preparedness & Response. Test to Treat | HHS/ASPR. Accessed October 21, 2022. – ident: bib1 article-title: Fact sheet: COVID-19 public health emergency transition roadmap – year: January 5, 2024 ident: bib20 article-title: 9 Things You Need to Know about Molnupiravir, a New COVID-19 Pill – volume: 58 start-page: 7 year: 2021 end-page: 14 ident: bib32 article-title: Regional and socioeconomic predictors of perceived ability to access coronavirus testing in the United States: results from a nationwide online COVID-19 survey publication-title: Ann. Epidemiol. – volume: 212 year: 2022 ident: bib52 article-title: A longitudinal study of COVID-19 disclosure stigma and COVID-19 testing hesitancy in the United States | Elsevier Enhanced Reader publication-title: Publ. Health – year: 2022 ident: bib10 article-title: The red/blue divide in COVID-19 vaccination rates continues: an update – reference: Raglow Z, Malani PN, Petty LA. Outpatient treatment for COVID-19. JAMA. Published online August 16, 2023. doi:10.1001/jama.2023.16666. – reference: Sharmin R, Rayna SE, Khalequzzaman M, Rahman KMT, Islam SS. COVID-19 Testing: Perceived Barriers Among the Urban Slum Dwellers of Dhaka, Bangladesh. doi:10.31219/OSF.IO/W3QPB. – volume: 5 start-page: 337 year: 2021 end-page: 348 ident: bib39 article-title: Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA publication-title: Nat. Human Behav. – reference: Oakley ERS and EM. Geospatial Disparities in Federal COVID-19 Test-to-Treat Program | EndNote Click. Accessed May 20, 2023. – volume: 17 start-page: 1954 year: 2021 end-page: 1963 ident: bib41 article-title: When fear and misinformation go viral: pharmacists' role in deterring medication misinformation during the “infodemic” surrounding COVID-19 publication-title: Res. Soc. Adm. Pharm. – volume: 5 year: 2022 ident: bib34 article-title: Misrepresentation and nonadherence regarding COVID-19 public health measures publication-title: JAMA Netw. Open – year: January 11, 2023 ident: bib3 article-title: COVID-19 provisional counts - weekly updates by select demographic and geographic characteristics – year: March 25, 2024 ident: bib19 article-title: 13 things to know about paxlovid publication-title: The Latest COVID-19 Pill – reference: NIH launches Home Test to Treat, a pilot COVID-19 telehealth program. National Institute of Biomedical Imaging and Bioengineering. Accessed September 14, 2023. – year: 2023 ident: bib16 article-title: Oral antiviral therapy utilization among adults with recent COVID-19 in the United States publication-title: J. Gen. Intern. Med. – volume: 16 year: 2021 ident: bib33 article-title: If you build it, will they come? Social, economic, and psychological determinants of COVID-19 testing decisions publication-title: PLoS One – volume: 4 year: 2021 ident: bib38 article-title: Black and latinx community perspectives on COVID-19 mitigation behaviors, testing, and vaccines publication-title: JAMA Netw. Open – year: 2022 ident: bib8 publication-title: Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity – volume: 2 start-page: 100066 year: 2022 ident: bib49 article-title: Determinants of COVID-19 testing among late middle-aged and older adults: applying the health belief model publication-title: Aging Health Res – ident: bib51 article-title: Estimated COVID-19 burden – volume: 18 start-page: 1 year: 2021 end-page: 8 ident: bib50 article-title: Perceived barriers to COVID-19 testing publication-title: Int. J. Environ. Res. Publ. Health – reference: Verderosa MAB and AD. Use of Antiviral Agents and other Therapies for COVID-19 | EndNote Click. Accessed May 20, 2023. – volume: 13 year: 2022 ident: bib37 article-title: Risky business: a mixed methods study of decision-making regarding COVID-19 risk at a public university in the United States publication-title: Front. Psychol. – reference: Leonhardt D. The Power of Paxlovid. The New York Times. – reference: . Published October 7, 2022. Accessed November 8, 2022. – volume: 22 start-page: 96 year: 2022 ident: bib11 article-title: Vaccination, politics and COVID-19 impacts publication-title: BMC Publ. Health – volume: 18 start-page: 4848 year: 2021 ident: bib7 article-title: Time trends in racial/ethnic differences in COVID-19 infection and mortality publication-title: Int. J. Environ. Res. Publ. Health – ident: bib15 article-title: The biden-harris administration will end COVID-19 vaccination requirements for federal employees, contractors, international travelers, head start educators, and CMS-certified facilities. The white house – volume: 111 start-page: 778 year: 2021 end-page: 781 ident: bib30 article-title: Contact tracing could exacerbate COVID-19 health disparities: the role of economic precarity and stigma publication-title: Am. J. Publ. Health – volume: 3 start-page: e72 year: 2021 end-page: e75 ident: bib40 article-title: Application of unsupervised machine learning to identify and characterise hydroxychloroquine misinformation on Twitter publication-title: Lancet Digit Health – volume: 39 start-page: 1080 year: 2021 end-page: 1086 ident: bib12 article-title: Predictors of intention to vaccinate against COVID-19: results of a nationwide survey publication-title: Vaccine – ident: bib45 article-title: Medscape survey finds reasons paxlovid IS UNDERPRESCRIBED for those 65 and older, despite its effectiveness against COVID complications – volume: 6 start-page: 171 year: 2018 end-page: 180 ident: bib47 article-title: Best practices in collecting online data with asian, black, latino, and white respondents: evidence from the 2016 collaborative multiracial post-election survey publication-title: Polit Groups Identities – volume: 24 start-page: 589 year: 2021 end-page: 594 ident: bib31 article-title: County-level determinants of COVID-19 testing and cases: are there racial/ethnic disparities in Texas? – volume: 59 start-page: 157 year: 2020 ident: bib36 article-title: Relationships between initial COVID-19 risk perceptions and protective health behaviors: a national survey publication-title: Am. J. Prev. Med. – year: 2020 ident: bib4 article-title: COVID-19 Mortality by Usual Occupation and Industry: 46 States and New York City, United States – volume: 174 start-page: 936 year: 2021 end-page: 944 ident: bib29 article-title: Spatial inequities in COVID-19 testing, positivity, confirmed cases, and mortality in 3 U.S. Cities : an ecological study publication-title: Ann. Intern. Med. – volume: 27 start-page: 1907 year: 2022 end-page: 1917 ident: bib13 article-title: COVID-19 vaccine acceptance: influential roles of political party and religiosity publication-title: Psychol. Health Med. – reference: . – volume: 176 start-page: 77 year: 2023 end-page: 84 ident: bib21 article-title: Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system publication-title: Ann. Intern. Med. – year: 2023 ident: bib22 article-title: Information Sheet: Paxlovid Eligibility and Effectiveness – ident: bib25 article-title: How test to treat works for individuals and families | HHS/ASPR – volume: 10 start-page: 476 year: 2022 ident: bib14 article-title: Does hospitalization change the perception of COVID-19 vaccines among unvaccinated patients? publication-title: Vaccines – volume: 28 year: 2022 ident: bib44 article-title: Editorial: rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with paxlovid and Molnupiravir publication-title: Med Sci Monit Int Med J Exp Clin Res – volume: 376 start-page: 613 year: 2017 end-page: 615 ident: bib46 article-title: The common Rule, updated publication-title: N. Engl. J. Med. – volume: 28 start-page: 1624 year: 2022 end-page: 1632 ident: bib5 article-title: COVID-19 symptoms and deaths among healthcare workers, United States publication-title: Emerg. Infect. Dis. – volume: 28 start-page: 1624 issue: 8 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib5 article-title: COVID-19 symptoms and deaths among healthcare workers, United States publication-title: Emerg. Infect. Dis. doi: 10.3201/eid2808.212200 – volume: 111 start-page: 778 issue: 5 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib30 article-title: Contact tracing could exacerbate COVID-19 health disparities: the role of economic precarity and stigma publication-title: Am. J. Publ. Health doi: 10.2105/AJPH.2021.306244 – ident: 10.1016/j.puhip.2024.100519_bib15 – year: 2023 ident: 10.1016/j.puhip.2024.100519_bib16 article-title: Oral antiviral therapy utilization among adults with recent COVID-19 in the United States publication-title: J. Gen. Intern. Med. doi: 10.1007/s11606-023-08106-6 – volume: 28 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib44 article-title: Editorial: rebound COVID-19 and cessation of antiviral treatment for SARS-CoV-2 with paxlovid and Molnupiravir publication-title: Med Sci Monit Int Med J Exp Clin Res – volume: 6 issue: 8 year: 2023 ident: 10.1016/j.puhip.2024.100519_bib42 article-title: Communication of COVID-19 misinformation on social media by physicians in the US publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2023.28928 – volume: 3 start-page: e72 issue: 2 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib40 article-title: Application of unsupervised machine learning to identify and characterise hydroxychloroquine misinformation on Twitter publication-title: Lancet Digit Health doi: 10.1016/S2589-7500(20)30318-6 – volume: 16 issue: 7 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib33 article-title: If you build it, will they come? Social, economic, and psychological determinants of COVID-19 testing decisions publication-title: PLoS One doi: 10.1371/journal.pone.0252658 – volume: 15 start-page: 7899 issue: 5 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib35 article-title: COVID-19 point-of-care diagnostics: present and future publication-title: ACS Nano doi: 10.1021/acsnano.1c02981 – volume: 59 start-page: 157 issue: 2 year: 2020 ident: 10.1016/j.puhip.2024.100519_bib36 article-title: Relationships between initial COVID-19 risk perceptions and protective health behaviors: a national survey publication-title: Am. J. Prev. Med. doi: 10.1016/j.amepre.2020.05.001 – ident: 10.1016/j.puhip.2024.100519_bib10 – year: 2022 ident: 10.1016/j.puhip.2024.100519_bib26 – year: 2022 ident: 10.1016/j.puhip.2024.100519_bib8 – year: 2022 ident: 10.1016/j.puhip.2024.100519_bib6 – volume: 24 start-page: 589 issue: 5 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib31 article-title: County-level determinants of COVID-19 testing and cases: are there racial/ethnic disparities in Texas? – ident: 10.1016/j.puhip.2024.100519_bib48 doi: 10.31219/osf.io/w3qpb – year: 2023 ident: 10.1016/j.puhip.2024.100519_bib2 – volume: 2 start-page: 100066 issue: 2 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib49 article-title: Determinants of COVID-19 testing among late middle-aged and older adults: applying the health belief model publication-title: Aging Health Res doi: 10.1016/j.ahr.2022.100066 – year: 2020 ident: 10.1016/j.puhip.2024.100519_bib4 – volume: 39 start-page: 1080 issue: 7 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib12 article-title: Predictors of intention to vaccinate against COVID-19: results of a nationwide survey publication-title: Vaccine doi: 10.1016/j.vaccine.2021.01.010 – volume: 22 start-page: 96 issue: 1 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib11 article-title: Vaccination, politics and COVID-19 impacts publication-title: BMC Publ. Health doi: 10.1186/s12889-021-12432-x – ident: 10.1016/j.puhip.2024.100519_bib43 – ident: 10.1016/j.puhip.2024.100519_bib24 – volume: 4 issue: 7 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib38 article-title: Black and latinx community perspectives on COVID-19 mitigation behaviors, testing, and vaccines publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2021.17074 – volume: 212 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib52 article-title: A longitudinal study of COVID-19 disclosure stigma and COVID-19 testing hesitancy in the United States | Elsevier Enhanced Reader publication-title: Publ. Health doi: 10.1016/j.puhe.2022.08.003 – year: 2023 ident: 10.1016/j.puhip.2024.100519_bib22 – volume: 6 start-page: 171 issue: 1 year: 2018 ident: 10.1016/j.puhip.2024.100519_bib47 article-title: Best practices in collecting online data with asian, black, latino, and white respondents: evidence from the 2016 collaborative multiracial post-election survey publication-title: Polit Groups Identities doi: 10.1080/21565503.2017.1419433 – volume: 13 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib37 article-title: Risky business: a mixed methods study of decision-making regarding COVID-19 risk at a public university in the United States publication-title: Front. Psychol. doi: 10.3389/fpsyg.2022.926664 – year: 2024 ident: 10.1016/j.puhip.2024.100519_bib19 article-title: 13 things to know about paxlovid – volume: 112 start-page: 518 issue: 3 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib28 article-title: Racial/ethnic segregation and access to COVID-19 testing: spatial distribution of COVID-19 testing sites in the four largest highly segregated cities in the United States publication-title: Am. J. Publ. Health doi: 10.2105/AJPH.2021.306558 – volume: 27 start-page: 1907 issue: 9 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib13 article-title: COVID-19 vaccine acceptance: influential roles of political party and religiosity publication-title: Psychol. Health Med. doi: 10.1080/13548506.2021.1969026 – volume: 18 start-page: 1 issue: 5 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib50 article-title: Perceived barriers to COVID-19 testing publication-title: Int. J. Environ. Res. Publ. Health doi: 10.3390/ijerph18052278 – volume: 176 start-page: 77 issue: 1 year: 2023 ident: 10.1016/j.puhip.2024.100519_bib21 article-title: Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. Health system publication-title: Ann. Intern. Med. doi: 10.7326/M22-2141 – volume: 174 start-page: 936 issue: 7 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib29 article-title: Spatial inequities in COVID-19 testing, positivity, confirmed cases, and mortality in 3 U.S. Cities : an ecological study publication-title: Ann. Intern. Med. doi: 10.7326/M20-3936 – volume: 18 start-page: 4848 issue: 9 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib7 article-title: Time trends in racial/ethnic differences in COVID-19 infection and mortality publication-title: Int. J. Environ. Res. Publ. Health doi: 10.3390/ijerph18094848 – volume: 376 start-page: 613 issue: 7 year: 2017 ident: 10.1016/j.puhip.2024.100519_bib46 article-title: The common Rule, updated publication-title: N. Engl. J. Med. doi: 10.1056/NEJMp1700736 – ident: 10.1016/j.puhip.2024.100519_bib18 – volume: 17 start-page: 1954 issue: 1 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib41 article-title: When fear and misinformation go viral: pharmacists' role in deterring medication misinformation during the “infodemic” surrounding COVID-19 publication-title: Res. Soc. Adm. Pharm. doi: 10.1016/j.sapharm.2020.04.032 – volume: 5 start-page: 337 issue: 3 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib39 article-title: Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA publication-title: Nat. Human Behav. doi: 10.1038/s41562-021-01056-1 – year: 2024 ident: 10.1016/j.puhip.2024.100519_bib20 – volume: 58 start-page: 7 year: 2021 ident: 10.1016/j.puhip.2024.100519_bib32 article-title: Regional and socioeconomic predictors of perceived ability to access coronavirus testing in the United States: results from a nationwide online COVID-19 survey publication-title: Ann. Epidemiol. doi: 10.1016/j.annepidem.2021.03.001 – volume: 5 issue: 10 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib34 article-title: Misrepresentation and nonadherence regarding COVID-19 public health measures publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2022.35837 – volume: 10 start-page: 476 issue: 3 year: 2022 ident: 10.1016/j.puhip.2024.100519_bib14 article-title: Does hospitalization change the perception of COVID-19 vaccines among unvaccinated patients? publication-title: Vaccines doi: 10.3390/vaccines10030476 – ident: 10.1016/j.puhip.2024.100519_bib17 doi: 10.1001/jama.2023.16666 – ident: 10.1016/j.puhip.2024.100519_bib23 – ident: 10.1016/j.puhip.2024.100519_bib27 |
| SSID | ssj0002511784 |
| Score | 2.279469 |
| Snippet | Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona Virus... AbstractObjectivesKnowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel... Image 1 Objectives: Knowledge, access, and use of testing and antiviral treatments is critical to managing and mitigating the continuing burden of the novel Corona... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 100519 |
| SubjectTerms | Antiviral treatment COVID-19 attitudes and knowledge Health communication Health disparities Infectious disease prevention Internal Medicine Original Research Public Health |
| Title | Beliefs about COVID-19 testing and treatment: A national survey of Black and White adults |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666535224000569 https://www.clinicalkey.es/playcontent/1-s2.0-S2666535224000569 https://dx.doi.org/10.1016/j.puhip.2024.100519 https://www.ncbi.nlm.nih.gov/pubmed/39027346 https://www.proquest.com/docview/3082630363 https://pubmed.ncbi.nlm.nih.gov/PMC11255099 https://doaj.org/article/572e9dcc10d84a25a97efcaf66725a65 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQV2wQiFegVEZiSaTEb7NrC1VBAhZQVFaWY1_TYZGpmhmk_n2vnWQ0A4huWCax4-T4da5zckzIKxa4UAkjVSF5qEWnfW1ktLVXAdmt4mCLldLHT-r0THw4l-dbW31lTdhoDzwChwE7AxtDaJtohGfSWw0p-KSUxgNV3Esb22wFU3kMzsRZGzHbDBVB1-X6YpEdKpnI0gCZvXW2pqLi2L8zI_3JOH8XTm7NRCf3yb2JQtLD8dEfkDvQPyTfjwDZZBpoURrT48_f3r-tW0tX2UWj_0F9H-lGVP6GHtJ5FZAO66tfcE2XiZbFvJKybJtHizfH8Iicnbz7enxaT9sm1EEavqpF0ByA2YihX0pCajA26hgxdNFNh5TKWJW4BNOKFFoLtmvAeNNANOA56_hjstcve3hKqGk9iwCiScAF4m1kx6IIxluZZ3pWkdczgu5ydMdws2zspyuAuwy4GwGvyFFGeZM0W1uXE1jhbqpwd1uFV0TMdeTmv0dxvMMbLf5dtv5bNhimPju41g3MNe4LUhaVTW-yuhbpIeZUm5wTLRnpxu1FvpybkMNOm7_E-B6W68FljyCVyQOvyJOxSW1A4bZYDqmKmJ3GtoPa7pV-cVGMwZE7Y8Bp7bP_gfNzcje_yyjd2Sd7q6s1vEACtuoOSl87KCtjN14xLmY |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Beliefs+about+COVID-19+testing+and+treatment%3A+A+national+survey+of+Black+and+White+adults&rft.jtitle=Public+health+in+practice+%28Oxford%2C+England%29&rft.au=Siminoff%2C+Laura+A.&rft.au=Barker%2C+K.+Laura&rft.au=Blunt%2C+Ryan&rft.au=Litsas%2C+Diana&rft.date=2024-12-01&rft.pub=Elsevier&rft.eissn=2666-5352&rft.volume=8&rft_id=info:doi/10.1016%2Fj.puhip.2024.100519&rft.externalDocID=PMC11255099 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26665352%2FS2666535224X00026%2Fcov150h.gif |